Today we started work in our new office at KNSM-laan 17 in Amsterdam. Find the complete address in the footer of this website.
Sign up
Stay up-to-date with SOMOs Newsletter
related content
Fintech’s red flags
Fintech is expanding – and so are the risks
Fintech – the use of technology to deliver financial services – is expanding globally. Millions of people now use financial technology applications and tools on a regular basis and access services. Yet, as SOMO’s new…
SOMO is delighted to welcome Fernanda Hopenhaym as the newest member of its Supervisory Board.
Fernanda Hopenhaym is the Co-Executive Director of the Project on Organizing, Development, Education and Research (PODER), an organisation in Latin America dedicated to corporate accountability. She is an expert on the impacts of corporations on…
How Mozambique’s tax treaties enable tax avoidance
Tax treaties deprive Mozambique of hundreds of millions of US dollars
Mozambique’s tax treaty network is depriving the country of hundreds of millions of US dollars in tax revenue each year, particularly through its treaties with Mauritius and the United Arab Emirates (UAE). Seventy percent of…
Vacancy: Climate Justice Researcher
Are you concerned about the looming climate crisis and critical of how powerful corporations that got us into this crisis are now seeking to ‘lead’ an unjust energy transition that will further entrench their interests?…
SOMO launches The Counter – a global help desk for activists challenging corporate power
We are delighted to announce that SOMO is setting up a pro bono investigations unit to help activists counter corporate power! (Press Release English | Spanish | French | Dutch) The Counter, which will go live…
Electric vehicles are a good thing – but not if everybody owns one
As the EU prepares to formally approve a new regulation to improve the sustainability of batteries used in electric vehicles, SOMO has published a powerful set of data visualisations showing the huge planned increase in…
Big Pharma raked in USD 90 billion in profits with COVID-19 vaccines
Pfizer, BioNTech, Moderna, and Sinovac made an extraordinary USD 90 billion in profits on their COVID-19 vaccines and medicines in 2021 and 2022. SOMO’s new report Pharma’s Pandemic Profits shows that these enormous gains are…
Pharma’s pandemic profits
Pharma profits from COVID-19 vaccines
